Fenoterol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fenoterol: From Bronchodilation to Multiple System Atrophy
One-Sentence Summary
Fenoterol is a short-acting β2-adrenergic receptor agonist historically used for bronchodilation (e.g., asthma/COPD symptom relief), though formal original-indication and licensing data were not available in this evidence pack. The TxGNN model’s top-ranked prediction for repurposing is Multiple System Atrophy, but this pairing is currently supported by 0 clinical trials and 0 publications — it is a pure model-generated signal with no mechanistic or empirical corroboration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bronchodilation (β2-adrenergic agonist) — derived from model rationale text; no SAHPRA/formulary licensing data available |
| Predicted New Indication | Multiple System Atrophy |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L5 (model prediction only, no studies) |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Fenoterol was not available in DrugBank for this evidence pack (data gap, high severity). Based on the repurposing model’s own rationale text, Fenoterol is understood as a short-acting β2-adrenergic receptor agonist, primarily used for bronchial smooth-muscle relaxation.
Multiple System Atrophy (MSA), however, is a neurodegenerative disorder whose core pathology is autonomic nervous system degeneration — most notably orthostatic hypotension and dysautonomia. There is no established pharmacological pathway connecting β2-receptor agonism to the neurodegenerative processes underlying MSA. According to the evidence pack’s own assessment, this high TxGNN score appears to reflect network-topology inference rather than an interpretable receptor–disease mechanism, and it is not corroborated by any clinical trial or literature evidence to date.
In short: this is a high-confidence model score without a plausible mechanistic story or any supporting real-world data — the combination that most warrants caution before any further investment of review resources.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Multiple System Atrophy) carries a high TxGNN score but zero supporting clinical trials, zero literature, and a mechanistic rationale that the evidence pack itself flags as biologically unsupported (decision stage S0). There is no basis to advance this pairing.
To proceed, the following is needed:
- Confirmed original indication and SAHPRA/PI data for Fenoterol (currently a blocking data gap)
- DrugBank-sourced mechanism-of-action confirmation
- Any preclinical or case-level evidence specifically linking β2-adrenergic agonism to autonomic/neurodegenerative pathology in MSA, before this candidate is reconsidered
Note on other candidates in this batch: Among the 10 predictions reviewed for Fenoterol, the strongest evidentiary support was for anaphylaxis (rank 9, score 98.28%, evidence level L4), backed by 11 animal-study publications (1977–1989) showing β2-agonists inhibit antigen-induced histamine release — though all evidence is preclinical and decades old, with no modern or human data. Two candidates — sinoatrial block and sinoatrial node disease (ranks 7–8) — reached decision stage S1 with a plausible positive-chronotropic rationale but no direct evidence. Conversely, the open-angle glaucoma predictions (ranks 4, 6, 10) show a mechanistically contradictory signal (β2-agonism may raise rather than lower intraocular pressure) and should be deprioritized. If resources allow further evaluation in this batch, anaphylaxis is the more defensible next research question — not the top-ranked MSA prediction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.